Table 2 Analysis by CA19-9 subgroup
Group | Number of patients | Median CA19-9 decline, absolute value (U cc −3 ) (95% CI) | No. of pts. censored for survival | Median survival (mos) (95% CI) | No. of pts. censored for TTF | Median time to treatment failure (mos) (95% CI) |
|---|---|---|---|---|---|---|
No decline in CA19-9 | 19 (25.0%) | N/A | 1 (5.3%) | 4.31 (3.00–5.20) | 1 (5.3%) | 1.35 (1.00–2.76) |
0–25% decline | 5 (6.6%) | 114.0 (83–5500) | 0 | 6.02 (3.80–9.67) | 0 | 3.36 (1.38–5.72) |
26–50% decline | 12 (15.8%) | 1424.0 (26–55 000) | 0 | 7.04 (5.16–10.00) | 3 (25.0%) | 3.60 (2.07–4.14) |
51–75% decline | 16 (21.1%) | 2751.2 (160–279 074) | 2 (12.5%) | 7.55 (5.16–10.80) | 2 (12.5%) | 3.80 (2.24–4.44) |
>75% decline | 24 (31.6%) | 3251.5 (236–263 490) | 2 (8.3%) | 12.00 (9.21–13.59) | 5 (20.8%) | 6.00 (4.87–14.50) |
Log-rank χ2 | 31.20 (df=4, P<0.001) | 50.34 (df=4, P<0.001) |
